| Jul 1 |
Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
|
| Jun 25 |
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
|
| Jun 1 |
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
|
| May 30 |
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
|
| May 24 |
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
|
| May 23 |
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
|
| May 6 |
The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts
|
| May 3 |
Werewolf Therapeutics GAAP EPS of -$0.39, revenue of $0.74M
|
| May 3 |
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
| Apr 24 |
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
